Caleb C. McLeod
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Caleb C. McLeod has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Karen K. Tan
Loma Linda University Medical Center , Loma Linda, California
2 shared publications Hadeel Al-Fayiz
Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, CA, USA
1 shared publicationJacinda Abdul-Mutkabbir
University of California San Diego , La Jolla, California
1 shared publication- Jacinda C. Abdul-Mutakabbir
Department of Pharmacy Practice and Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, USA
1 shared publication Sasha Rodriguez
Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, CA, USA
1 shared publication
Latest Publications
- Open Access
- 29 November 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e214
Examining racial and social vulnerability disparities in the outpatient treatment of uncomplicated cystitis at a Southern California Academic Hospital
Racially and ethnically minoritized (REM) patients are disproportionately impacted by infectious diseases. In our study, REM patients were more likely to receive care for urinary tract infections in the emergency department or urgent care, were younger, and were more likely to have higher social vulnerability.
- 29 November 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e214
Open AccessExamining racial and social vulnerability disparities in the outpatient treatment of uncomplicated cystitis at a Southern California Academic Hospital
Racially and ethnically minoritized (REM) patients are disproportionately impacted by infectious diseases. In our study, REM patients were more likely to receive care for urinary tract infections in the emergency department or urgent care, were younger, and were more likely to have higher social vulnerability.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
586. Characterizing the Clinical Outcomes of Patients with Positive Blood Cultures Not Identified by Rapid Diagnostics
Rapid diagnostics tools (RDTs) have improved clinical outcomes by prompt identification of pathogens in blood cultures, leading to the initiation of directed empiric antibiotic therapy. However, several organisms are unidentified by RDTs, which may delay appropriate antimicrobial therapy and increase mortality risks. Studies characterizing these off-panel organisms are limited, and guidance for antimicrobial therapy is unavailable. We sought to characterize the off-panel organisms encountered in blood cultures and provide important insights into the pathogens that may be missed by RDTs to improve the clinical management of bacteremia. This was a retrospective study conducted from 8/2018 to 5/2021 at an academic medical center in Loma Linda, California. All adult patients with blood cultures processed on the Verigene (RDT) platform were screened for inclusion. Patients were included if Verigene was unable to detect a target organism. Species identification and antimicrobial susceptibility were performed with MicroScan WalkAway or sent to a reference laboratory if unidentifiable by MicroScan. Patient demographics, comorbidities, suspected source of infection, discharge disposition, and readmissions were determined by chart review. Out of 1,071 blood cultures screened, 80 (47 Gram-positive [GP] and 33 Gram-negative [GN] isolates were not identified by Verigene. While not significant, patients with off-panel GN bacteremia were older (65.5 vs 58 years, p=0.074) and had longer durations of stay (11 vs 9 days, p=0.149) than patients with unidentified GP isolates. Patients with off-panel GN isolates were also more likely to have a comorbid malignancy than those with off-panel GP isolates (42% vs 26%, p=0.112) and more likely to present with severe sepsis (89% vs 79%, p =0.376), though these differences were not significant. Cefepime and piperacillin/tazobactam were reliable agents for GN isolates (11/13, 18/21), and vancomycin retained activity against unidentified GP isolates. Patients with GN organisms not identified by RDTs are more likely to present with severe sepsis and less likely to survive hospital discharge than those with unidentified GP organisms. Further research is needed to guide antimicrobial therapy for off-panel results. Jacinda Abdul-Mutkabbir, PharmD,MPH, Entasis Therapeutics: Advisor/Consultant|Entasis Therapeutics: Honoraria|shionogi: Advisor/Consultant|shionogi: Honoraria
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access586. Characterizing the Clinical Outcomes of Patients with Positive Blood Cultures Not Identified by Rapid Diagnostics
Rapid diagnostics tools (RDTs) have improved clinical outcomes by prompt identification of pathogens in blood cultures, leading to the initiation of directed empiric antibiotic therapy. However, several organisms are unidentified by RDTs, which may delay appropriate antimicrobial therapy and increase mortality risks. Studies characterizing these off-panel organisms are limited, and guidance for antimicrobial therapy is unavailable. We sought to characterize the off-panel organisms encountered in blood cultures and provide important insights into the pathogens that may be missed by RDTs to improve the clinical management of bacteremia. This was a retrospective study conducted from 8/2018 to 5/2021 at an academic medical center in Loma Linda, California. All adult patients with blood cultures processed on the Verigene (RDT) platform were screened for inclusion. Patients were included if Verigene was unable to detect a target organism. Species identification and antimicrobial susceptibility were performed with MicroScan WalkAway or sent to a reference laboratory if unidentifiable by MicroScan. Patient demographics, comorbidities, suspected source of infection, discharge disposition, and readmissions were determined by chart review. Out of 1,071 blood cultures screened, 80 (47 Gram-positive [GP] and 33 Gram-negative [GN] isolates were not identified by Verigene. While not significant, patients with off-panel GN bacteremia were older (65.5 vs 58 years, p=0.074) and had longer durations of stay (11 vs 9 days, p=0.149) than patients with unidentified GP isolates. Patients with off-panel GN isolates were also more likely to have a comorbid malignancy than those with off-panel GP isolates (42% vs 26%, p=0.112) and more likely to present with severe sepsis (89% vs 79%, p =0.376), though these differences were not significant. Cefepime and piperacillin/tazobactam were reliable agents for GN isolates (11/13, 18/21), and vancomycin retained activity against unidentified GP isolates. Patients with GN organisms not identified by RDTs are more likely to present with severe sepsis and less likely to survive hospital discharge than those with unidentified GP organisms. Further research is needed to guide antimicrobial therapy for off-panel results. Jacinda Abdul-Mutkabbir, PharmD,MPH, Entasis Therapeutics: Advisor/Consultant|Entasis Therapeutics: Honoraria|shionogi: Advisor/Consultant|shionogi: Honoraria